STOCK TITAN

[SCHEDULE 13G/A] Aligos Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Adage Capital Management, L.P., together with reporting persons Robert Atchinson and Phillip Gross, disclosed beneficial ownership of 210,000 shares of Aligos Therapeutics common stock, representing 3.90% of the outstanding class on the basis indicated in the filing. The position includes 70,000 shares issuable upon exercise of warrants. The filing shows no sole voting or dispositive power and reports the stake as held with shared voting and dispositive power. The certifying statement indicates the securities were acquired and are held in the ordinary course of business and not for the purpose of changing control.

Adage Capital Management, L.P., insieme alle persone che riportano Robert Atchinson e Phillip Gross, ha comunicato la titolarità beneficiaria di 210.000 azioni ordinarie di Aligos Therapeutics, pari al 3,90% della classe in circolazione secondo quanto indicato nel deposito. La posizione comprende 70.000 azioni ottenibili mediante esercizio di warrant. Il deposito segnala assenza di poteri unilaterali di voto o di disposizione e riporta che la partecipazione è detenuta con poteri di voto e di disposizione condivisi. La dichiarazione certifica che i titoli sono stati acquisiti e sono detenuti nell'ordinario svolgimento dell'attività e non allo scopo di modificarne il controllo.

Adage Capital Management, L.P., junto con las personas informantes Robert Atchinson y Phillip Gross, divulgó la titularidad beneficiaria de 210.000 acciones ordinarias de Aligos Therapeutics, que representan el 3,90% de la clase en circulación según consta en la presentación. La posición incluye 70.000 acciones susceptibles de emitirse al ejercerse warrants. El documento indica que no existe poder exclusivo de voto o de disposición y reporta la participación como mantenida con poderes de voto y de disposición compartidos. La declaración certifica que los valores se adquirieron y se mantienen en el curso ordinario del negocio y no con el propósito de cambiar el control.

Adage Capital Management, L.P.는 보고인 Robert Atchinson 및 Phillip Gross와 함께 Aligos Therapeutics 보통주 210,000주의 실질적 소유권을 공시했으며, 이는 신고서에 기재된 바와 같이 발행 주식의 3.90%에 해당합니다. 해당 지분에는 워런트 행사로 취득 가능한 70,000주가 포함되어 있습니다. 제출서류에는 단독 의결권 또는 처분권 없음으로 기재되어 있으며, 지분은 공동 의결권 및 처분권으로 보고됩니다. 인증 진술에는 이 증권들이 영업상 통상적인 과정에서 취득되어 보유되고 있으며 지배권 변경 목적이 아니라는 내용이 명시되어 있습니다.

Adage Capital Management, L.P., conjointement avec les personnes déclarante Robert Atchinson et Phillip Gross, a divulgué la propriété bénéficiaire de 210 000 actions ordinaires d'Aligos Therapeutics, représentant 3,90 % de la classe en circulation, selon les indications du dépôt. La position comprend 70 000 actions susceptibles d'être émises par l'exercice de warrants. Le dépôt indique aucun pouvoir de vote ou de disposition exclusif et signale que la participation est détenue avec pouvoirs de vote et de disposition partagés. La déclaration de certification précise que les titres ont été acquis et sont détenus dans le cours normal des affaires et non dans le but de modifier le contrôle.

Adage Capital Management, L.P. hat zusammen mit den meldenden Personen Robert Atchinson und Phillip Gross den wirtschaftlichen Besitz von 210.000 Aktien der Stammaktien von Aligos Therapeutics offengelegt, was gemäß der Einreichung 3,90 % der ausstehenden Klasse entspricht. Die Position umfasst 70.000 Aktien, die durch Ausübung von Warrants ausgegeben werden können. Die Einreichung weist keine alleinige Stimm- oder Verfügungsgewalt aus und meldet die Beteiligung als mit geteilten Stimm- und Verfügungsrechten gehalten. Die Bestätigung erklärt, dass die Wertpapiere im gewöhnlichen Geschäftsbetrieb erworben und gehalten werden und nicht zum Zweck einer Kontrolländerung dienen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Passive investment filing discloses a 3.90% position (including warrants); below 5% threshold and shows no control intent.

The filing quantifies Adage's economic exposure to Aligos at 210,000 shares, inclusive of 70,000 warrants, and clarifies voting and dispositive power as shared rather than sole. For investors, this is a transparency disclosure consistent with passive ownership reporting; it does not signal an active campaign to influence corporate control. The reported percentage uses the issuer's stated share count as the denominator.

TL;DR: Schedule 13G/A indicates passive holding; governance impact is minimal given sub-5% ownership and certification of ordinary-course intent.

The filing names the manager (Adage Capital Management, L.P.) and two individuals as reporting persons and documents shared voting and dispositive authority. Inclusion of warrants in the beneficial ownership calculation is disclosed explicitly, which is important for accurate governance assessment. There is no indication of coordinated group action beyond the reporting persons or any intent to change issuer control.

Adage Capital Management, L.P., insieme alle persone che riportano Robert Atchinson e Phillip Gross, ha comunicato la titolarità beneficiaria di 210.000 azioni ordinarie di Aligos Therapeutics, pari al 3,90% della classe in circolazione secondo quanto indicato nel deposito. La posizione comprende 70.000 azioni ottenibili mediante esercizio di warrant. Il deposito segnala assenza di poteri unilaterali di voto o di disposizione e riporta che la partecipazione è detenuta con poteri di voto e di disposizione condivisi. La dichiarazione certifica che i titoli sono stati acquisiti e sono detenuti nell'ordinario svolgimento dell'attività e non allo scopo di modificarne il controllo.

Adage Capital Management, L.P., junto con las personas informantes Robert Atchinson y Phillip Gross, divulgó la titularidad beneficiaria de 210.000 acciones ordinarias de Aligos Therapeutics, que representan el 3,90% de la clase en circulación según consta en la presentación. La posición incluye 70.000 acciones susceptibles de emitirse al ejercerse warrants. El documento indica que no existe poder exclusivo de voto o de disposición y reporta la participación como mantenida con poderes de voto y de disposición compartidos. La declaración certifica que los valores se adquirieron y se mantienen en el curso ordinario del negocio y no con el propósito de cambiar el control.

Adage Capital Management, L.P.는 보고인 Robert Atchinson 및 Phillip Gross와 함께 Aligos Therapeutics 보통주 210,000주의 실질적 소유권을 공시했으며, 이는 신고서에 기재된 바와 같이 발행 주식의 3.90%에 해당합니다. 해당 지분에는 워런트 행사로 취득 가능한 70,000주가 포함되어 있습니다. 제출서류에는 단독 의결권 또는 처분권 없음으로 기재되어 있으며, 지분은 공동 의결권 및 처분권으로 보고됩니다. 인증 진술에는 이 증권들이 영업상 통상적인 과정에서 취득되어 보유되고 있으며 지배권 변경 목적이 아니라는 내용이 명시되어 있습니다.

Adage Capital Management, L.P., conjointement avec les personnes déclarante Robert Atchinson et Phillip Gross, a divulgué la propriété bénéficiaire de 210 000 actions ordinaires d'Aligos Therapeutics, représentant 3,90 % de la classe en circulation, selon les indications du dépôt. La position comprend 70 000 actions susceptibles d'être émises par l'exercice de warrants. Le dépôt indique aucun pouvoir de vote ou de disposition exclusif et signale que la participation est détenue avec pouvoirs de vote et de disposition partagés. La déclaration de certification précise que les titres ont été acquis et sont détenus dans le cours normal des affaires et non dans le but de modifier le contrôle.

Adage Capital Management, L.P. hat zusammen mit den meldenden Personen Robert Atchinson und Phillip Gross den wirtschaftlichen Besitz von 210.000 Aktien der Stammaktien von Aligos Therapeutics offengelegt, was gemäß der Einreichung 3,90 % der ausstehenden Klasse entspricht. Die Position umfasst 70.000 Aktien, die durch Ausübung von Warrants ausgegeben werden können. Die Einreichung weist keine alleinige Stimm- oder Verfügungsgewalt aus und meldet die Beteiligung als mit geteilten Stimm- und Verfügungsrechten gehalten. Die Bestätigung erklärt, dass die Wertpapiere im gewöhnlichen Geschäftsbetrieb erworben und gehalten werden und nicht zum Zweck einer Kontrolländerung dienen.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Includes 70,000 shares of Voting Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants.


SCHEDULE 13G




Comment for Type of Reporting Person: Includes 70,000 shares of Voting Common Stock issuable upon exercise of warrants.


SCHEDULE 13G




Comment for Type of Reporting Person: Includes 70,000 shares of Voting Common Stock issuable upon exercise of warrants.


SCHEDULE 13G



Adage Capital Management, L.P.
Signature:/s/ Robert Atchinson
Name/Title:By: Adage Capital Partners LLC, its General Partner, By: Robert Atchinson, its Managing Member
Date:08/12/2025
Robert Atchinson
Signature:/s/ Robert Atchinson
Name/Title:Robert Atchinson, individually
Date:08/12/2025
Phillip Gross
Signature:/s/ Phillip Gross
Name/Title:Phillip Gross, individually
Date:08/12/2025

FAQ

What stake did Adage Capital report in Aligos Therapeutics (ALGS)?

Adage Capital reported beneficial ownership of 210,000 shares, representing 3.90% of Aligos' outstanding common stock (including warrants).

Does the reported 3.90% for ALGS include warrants?

Yes. The reported amount includes 70,000 shares issuable upon exercise of warrants held by the investment vehicle referenced in the filing.

Who are the reporting persons on the Schedule 13G/A for ALGS?

The filing lists Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross as the reporting persons.

Does the filing indicate Adage intends to influence control of ALGS?

No. The filing includes a certification stating the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

How much voting or dispositive power does Adage report for ALGS shares?

The filing reports 0 sole voting power and 210,000 shared voting power, with corresponding 0 sole and 210,000 shared dispositive power.
Aligos Therapeutics, Inc.

NASDAQ:ALGS

ALGS Rankings

ALGS Latest News

ALGS Latest SEC Filings

ALGS Stock Data

53.18M
4.80M
10.44%
65.43%
6.41%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO